The deal was announced with fanfare in 2009 with a headline value of $1.24 billion, but was terminated recently as a result of disappointing phase III study results.
AstraZenenca and Targacept announced top line results from their phase III studies investigating efficacy, tolerability and safaty of TC-5214, which was being developed as an adjunct therapy to an antidepressant in patients with major depressive disorder and who did not respond adequately to initial antidepressant treatment.
The remaining part of this article is Premium content – see below for access options.
CP Insight – Premium content section
This is a premium content section and requires a paid subscription to access.
2011 Deal terminations of the year
Buy the report: Partnering Terms and Agreements in Psychiatry
Buy the report: Partnering Agreements in Depression
View the Partnering scorecard 2009
View the deal in full at Current Partnering (subscription required)